Get the physical examination report, when “high triglycerides” and “high low-density lipoprotein cholesterol (LDL-C)” prompt appears, most people’s first reaction is “to prevent myocardial infarction, cerebral infarction”. However, few people know that the harm of dyslipidemia goes far beyond cardiovascular disease – recent epidemiological studies have shown a significant association between elevated blood lipids and the risk of lung cancer, in which people with specific abnormal blood lipid indicators have a maximum increase of 46% in the risk of lung cancer. This finding breaks the perception that blood lipids are only related to cardiovascular diseases, and also provides a new perspective for the early prevention and screening of lung cancer. blood lipid monitor
1. Study revealed: Dyslipidemia, the “invisible contributor” to lung cancer risk?
In 2023, a study published by the Cancer Hospital team of Chinese Academy of Medical Sciences in the journal Cancer Epidemiology, Biomarkers & Prevention was the first to clarify the quantitative association between lipid profile and lung cancer risk. The study, which involved more than 100,000 Chinese adults followed for an average of 12 years, found that:
For each 1mmol/L increase in triglyceride (TG) level, the risk of lung cancer increased by 13%.
The risk of lung cancer increased by 16% per 1-unit increase in the ratio of low-density lipoprotein cholesterol (LDL-C) to high-density lipoprotein cholesterol (HDL-C).
However, when TG≥2.3mmol/L and LDL-C/HDL-C≥3.5, the risk of lung cancer increased by 46% compared with people with normal blood lipids, and this association was more significant in non-smokers. Similarly, the Harvard School of Public Health study also found that people with persistently elevated total cholesterol levels had a 30% increase in lung cancer mortality, with lung adenocarcinoma being the most strongly associated.
These studies are not alone. In the past five years, more than 20 epidemiological studies around the world have confirmed that dyslipidemia is positively associated with increased risk of lung cancer, especially in women, non-smokers and patients with lung adenocarcinoma. This means that dyslipidemia is no longer just a “warning signal” of cardiovascular disease, but more likely to become a “weathervane” that can not be ignored in the prevention of lung cancer.
2. Mechanism exploration: How do blood lipids “leverage” lung cancer?
The association between blood lipids and lung cancer is not accidental, but there are complex biological mechanisms behind it. There are three main pathways linking dyslipidemia and lung cancer risk:
2.1 Chronic inflammation: “cancerous soil” induced by lipid accumulation
When triglycerides and LDL-C are elevated in the blood, excessive lipids are deposited in the vascular endothelium and tissues to form oxidized low-density lipoprotein (ox-LDL). This substance activates inflammatory pathways in the body and causes macrophages to transform into foam cells, releasing a large number of inflammatory factors (such as TNF-α and IL-6). Long-term chronic inflammation can lead to a decrease in the repair ability of DNA damage, increase the probability of gene mutation, and inhibit the immune system’s surveillance of tumor cells, which provides a “hot spot” for the proliferation of lung cancer cells.
2.2 Metabolic disorders: insulin resistance and abnormal cell proliferation
Dyslipidemia is often accompanied by insulin resistance, a central feature of type 2 diabetes and the metabolic syndrome. Insulin resistance can lead to increased levels of insulin-like growth factor (IGF-1) in vivo, which can promote cell proliferation and inhibit cell apoptosis. There are a large number of IGF-1 receptors on the surface of lung cancer cells, and excessive IGF-1 will accelerate the growth and metastasis of lung cancer cells. In addition, elevated triglycerides can also affect the balance of intestinal flora, and the secondary bile acids produced can directly damage the intestinal and lung mucosa, further increasing the risk of cancer.
2.3 Oxidative stress: lipid peroxidation damages DNA
When blood lipids rise, the generation of free radicals in the body increases, which triggers lipid peroxidation and produces malondialdehyde (MDA) and other harmful substances. These substances can directly attack the DNA of cells, leading to chromosomal aberrations and gene mutations, especially EGFR, KRAS and other genes that are closely related to the occurrence of lung cancer. It was found that MDA level was 2.3-fold higher and the expression of 8-OHdG, a DNA damage marker, was 37% higher in lung tissues of people with dyslipidemia than in healthy people, which directly confirmed the role of lipid peroxidation in lung cancer. blood lipid profile analyzer
3. Population differences: Who needs to be especially vigilant?
Not all people with dyslipidemia had an increased risk of lung cancer, but the associations were more significant in the following groups:
3.1 Non-smoking Women: a “high risk group” with doubled risk
The Chinese Academy of Medical Sciences study showed that in non-smoking women, the risk of lung cancer in women with TG≥2.3mmol/L was 2.1 times higher than that in women with normal lipid levels, and the risk of lung adenocarcinoma was 2.7 times higher. This may be related to the effect of estrogen level on lipid metabolism in women: estrogen can promote the synthesis of triglyceride in the liver, and inhibit the clearance of HDL-C, resulting in dyslipidemia and more likely to cause inflammation and damage to lung cells.
3.2 Patients with lung adenocarcinoma: dyslipidemia is closely related to prognosis
Lung cancer is mainly divided into adenocarcinoma, squamous cell carcinoma and small cell carcinoma, among which lung adenocarcinoma has the strongest association with dyslipidemia. The study found that patients with lung adenocarcinoma who had preoperative dyslipidemia had a 52% increased risk of postoperative recurrence and a 31% decreased 5-year survival rate. This is because lung adenocarcinoma cells have a more active lipid metabolism, which requires a large amount of cholesterol and fatty acids to maintain proliferation, and dyslipidemia just provides sufficient “nutrition” for them.
3.3 Patients with metabolic syndrome: superposition of multiple risks
The risk of lung cancer in people with metabolic syndrome who had hypertension, diabetes and dyslipidemia was 3.2 times higher than that in healthy people. This is because metabolic disorders can lead to a synergistic effect of inflammation, oxidative stress, and insulin resistance in the body, which greatly accelerates the cancerous process of lung cells. blood lipid strip
4. Clinical implication: Blood lipid management, a “new target” for lung cancer prevention?
Although the association between dyslipidemia and lung cancer has been confirmed, blood lipid indicators have not been included in routine lung cancer screening. Nevertheless, the study offers new ideas for lung cancer prevention:
4.1 Blood lipid monitoring should be strengthened in high-risk population
For people with family history of lung cancer, long-term exposure to oil fumes or air pollution, and chronic lung diseases, it is recommended to monitor blood lipid every six months, focusing on triglyceride, LDL-C, and LDL-C/HDL-C ratio. If TG≥2.3mmol/L or LDL-C/HDL-C≥3.5, lung cancer screening, including LDCT and tumor marker detection, should be performed in time.
4.2 Lipid intervention can reduce the risk of lung cancer
According to the American Cancer Society, reducing TG to less than 1.7mmol/L through lifestyle intervention can reduce the risk of lung cancer by 28%. In contrast, the use of statins reduced LDL-C by 50% and lung cancer risk by 34%. However, the preventive effect of statins still needs to be confirmed by more clinical studies. At present, lipid-lowering drugs are not recommended only for the prevention of lung cancer.
4.3 Comprehensive management is the key
Lipid management should not rely on drugs alone, but also needs to be combined with lifestyle modification:
Diet: reduce intake of saturated fats and trans fats and increase intake of dietary fiber (e.g., whole grains, vegetables) and Omega-3 fatty acids (e.g., deep-sea fish, nuts);
Exercise: 150 minutes of moderate-intensity aerobic exercise per week, such as brisk walking and jogging, can effectively reduce triglyceride levels;
Quitting smoking and limiting alcohol: smoking can aggravate dyslipidemia and lung inflammation, and quitting alcohol can reduce liver lipid synthesis.
Weight control: For every 1kg/m² decrease in BMI, triglyceride can be reduced by 8%, and LDL-C can be reduced by 5%.
From “cardiovascular warning” to “lung cancer signal”, the management of blood lipids needs to be upgraded
The association between dyslipidemia and lung cancer has broken our traditional understanding of the harm of blood lipids. Although it is not clear that elevated lipids directly cause lung cancer, the significant association suggests that lipid management should not only be limited to cardiovascular disease prevention, but also be part of lung cancer prevention and control.
For ordinary people, paying attention to blood lipid indicators during regular physical examination and maintaining lipid stability through a healthy lifestyle can not only reduce the risk of myocardial infarction and cerebral infarction, but also may unconsciously reduce the probability of lung cancer. For high-risk groups of lung cancer, blood lipid monitoring is the “stealth radar” of early warning – timely detection and intervention of dyslipidemia may become an important defense line to prevent lung cancer.
In the future, with the deepening of research, blood lipid indicators are expected to become an important basis for lung cancer risk stratification, and even become a new target for lung cancer treatment. However, for now, paying attention to the management of blood lipids and maintaining a healthy lifestyle are still our most feasible “weapons” against the risk of lung cancer. handheld lipid analyzer
Post time: Mar-21-2026